These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 35968380)

  • 1. Pharmacotherapeutic management of insomnia and effects on sleep processes, neural plasticity, and brain systems modulating stress: A narrative review.
    Palagini L; Bianchini C
    Front Neurosci; 2022; 16():893015. PubMed ID: 35968380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea.
    Mason M; Cates CJ; Smith I
    Cochrane Database Syst Rev; 2015 Jul; (7):CD011090. PubMed ID: 26171909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insomnia in Elderly Patients: Recommendations for Pharmacological Management.
    Abad VC; Guilleminault C
    Drugs Aging; 2018 Sep; 35(9):791-817. PubMed ID: 30058034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sleep, insomnia and mental health.
    Palagini L; Hertenstein E; Riemann D; Nissen C
    J Sleep Res; 2022 Aug; 31(4):e13628. PubMed ID: 35506356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia.
    Najib J
    Clin Ther; 2006 Apr; 28(4):491-516. PubMed ID: 16750462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative clinical profiles of triazolam versus other shorter-acting hypnotics.
    Jonas JM; Coleman BS; Sheridan AQ; Kalinske RW
    J Clin Psychiatry; 1992 Dec; 53 Suppl():19-31; discussion 32-3. PubMed ID: 1336776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Main neuroendocrine features and therapy in primary sleep troubles.
    Amihăesei IC; Mungiu OC
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(3):862-6. PubMed ID: 23272543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reintroduction of quazepam: an update on comparative hypnotic and adverse effects.
    Moniri NH
    Int Clin Psychopharmacol; 2019 Nov; 34(6):275-285. PubMed ID: 31274695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eszopiclone: esopiclone, estorra, S-zopiclone, zopiclone--Sepracor.
    Drugs R D; 2005; 6(2):111-5. PubMed ID: 15777104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation.
    Dündar Y; Boland A; Strobl J; Dodd S; Haycox A; Bagust A; Bogg J; Dickson R; Walley T
    Health Technol Assess; 2004 Jun; 8(24):iii-x, 1-125. PubMed ID: 15193209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications.
    Greenblatt DJ; Zammit GK
    Expert Opin Drug Metab Toxicol; 2012 Dec; 8(12):1609-18. PubMed ID: 23126273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of Safety and Efficacy of Sleep Medicines in Older Adults.
    Schroeck JL; Ford J; Conway EL; Kurtzhalts KE; Gee ME; Vollmer KA; Mergenhagen KA
    Clin Ther; 2016 Nov; 38(11):2340-2372. PubMed ID: 27751669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological interventions for the treatment of insomnia: quantitative comparison of drug efficacy.
    Zheng X; He Y; Yin F; Liu H; Li Y; Zheng Q; Li L
    Sleep Med; 2020 Aug; 72():41-49. PubMed ID: 32544795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinically important drug interactions with zopiclone, zolpidem and zaleplon.
    Hesse LM; von Moltke LL; Greenblatt DJ
    CNS Drugs; 2003; 17(7):513-32. PubMed ID: 12751920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis.
    Stranks EK; Crowe SF
    J Clin Exp Neuropsychol; 2014; 36(7):691-700. PubMed ID: 24931450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone.
    Drover DR
    Clin Pharmacokinet; 2004; 43(4):227-38. PubMed ID: 15005637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sleep Markers in Psychiatry: Do Insomnia and Disturbed Sleep Play as Markers of Disrupted Neuroplasticity in Mood Disorders? A Proposed Model.
    Palagini L; Geoffroy PA; Riemann D
    Curr Med Chem; 2022; 29(35):5595-5605. PubMed ID: 34906053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit-risk assessment of zaleplon in the treatment of insomnia.
    Barbera J; Shapiro C
    Drug Saf; 2005; 28(4):301-18. PubMed ID: 15783240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs.
    Kumar A; Chanana P; Choudhary S
    Pharmacol Rep; 2016 Apr; 68(2):231-42. PubMed ID: 26922522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience.
    Hajak G
    Drug Saf; 1999 Dec; 21(6):457-69. PubMed ID: 10612270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.